In a joint statement released Tuesday, the CDC and FDA recommended pausing delivery of Johnson & Johnson’s COVID-19 vaccine while those agencies review data about a small number of blood clots seen in patients who received the vaccine. The pause is intended in part to enable healthcare providers to learn more about the potential for these adverse events and plan to respond to any they may see. Providers are asked to report any adverse events to the Vaccine Adverse Event Reporting System. The CDC’s Advisory Committee on Immunization Practices will meet Wednesday to further review these cases and consider their possible significance.
All Curi recommendations are based on current CDC criteria at the time of publication. CDC guidance for SARS-CoV-2 infection may, or may not, be adopted by state and local health departments to respond to rapidly changing local circumstances. Providers should always check with their local health department to see if the CDC’s guidance on any given topic has been modified (particularly if more restrictive) from the CDC’s recommended guidelines. Follow this link https://www.cdc.gov/publichealthgateway/healthdirectories/index.html for contact information to your state/local health department. If local recommendations vary from those of the CDC, and you are unsure what recommendations to follow, then it is safer to follow the more restrictive guidelines/recommendations.